Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Pelthos will report third quarter 2026 financial results November 12, 2026
- ➤Conference call and question-and-answer session scheduled for 8:30 a.m. Eastern Time
- ➤ZELSUVMI is approved for at-home molluscum contagiosum treatment
- ➤Pelthos portfolio includes XEPI for impetigo and XEGLYZE for head lice
DURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report third quarter 2026 financial results on Thursday, November 12, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time.
Date: Thursday, November 12, 2026 Time: 8:30 a.m. Eastern Time Toll Free:1-877-451-6152 International:1-201-389-0879 Conf.ID:13763737
Get started
Create a free account to read the full story.